medigraphic.com
Colegio de Medicina Interna de México.

2006, Number 6

<< Back Next >>

Med Int Mex 2006; 22 (6)

Insulin’s prescription to patients with diabetes mellitus in three zones of Mexican Republic

Amancio CO, Lara EA, González CA, Lavalle F, Velázquez MÒ

Language: Spanish
References: 12
Page: 497-500
PDF size: 274.22 Kb.


ABSTRACT

Objective: To know the percentage of patients with diabetes type 2 that receive insulin as part of their treatment.
Material and method: In three different cities (areas) of the Mexican Republic a survey was applied to patients with diabetes. In this survey it was possible to identify age, sex, residence, type of diabetes, type of insulin and how long they had been using it.
Results: The survey was applied to 4,516 patients with diabetes, 58% were women. Of the total of patients, 4,033 had diabetes type 2. Only 12.4% of patients with diabetes type 2 use insulin as part of their treatment; insulin NPH was the most used.
Conclusion: In Mexico, insulin is not an important part of the treatment for patients with diabetes type 2.


REFERENCES

  1. American Diabetes Association. Clinical Practice. Recommendations 2002. Diabetes Care 2002;1:S1-S131.

  2. Secretario de Salud. Programa de acción. Diabetes Mellitus. México: Secretaría de Salud, 2002.

  3. Funsalud. Instituto Nacional de la Nutrición Salvador Zubirán. Información para el paciente diabético. México: Funsalud IMNSZ,1999.

  4. Tapia Conyer R. Manual para el manejo de insulina. México: Secretaría de Salud, 2005.

  5. United Kingdom Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:37-853.

  6. Lerman IG, Villa AR, Llaca Martínez C. The prevalence of diabetes and associated coronary risk factor in urban and rural older Mexican populations. J Am Geriatr Soc 1998;46:1387-95.

  7. Owers DR, Zinman B, Bolli G. Insulin today and beyond. Lancet 2001;358:739-46.

  8. Riddle MC. Evening insulin strategy. Diabetes Care 1990;13:676-86.

  9. Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25:330-6.

  10. Riddle M, Rosenstock J, HOE901/4002 Study Group. Treatment to target study: insulin glargine vs NPH insulin added to oral therapy of type 2 diabetes. Successful control with less nocturnal hypoglycemia [abstract]. Diabetes 2002;51(suppl 2):A113.

  11. Uso de insulinas en el tratamiento de la diabetes tipo 1 y 2. México: Secretaría de Salud, 2005.

  12. Gallegos FO, Velázquez MU, Pliego P, Martin MA, Lara Esqueda A y col. Comunicación y perspectiva de audiencias: una investigación cualitativa para la diabetes. Endocrinología y Nutrición 2000;8(1):5-13.




2020     |     www.medigraphic.com